There is no clear evidence of an increased risk for myocardial infarction, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson's disease (PD), a ...

Company states the realisation of generic competition is still neither certain nor imminent Orion Corporation has been informed that Sun Pharma Global, Inc. has filed an Abbreviated New Drug ...

Ajanta Pharma receives final approval from USFDA for Entacapone tablets, used in the treatment of Parkinson's disease ...

Mylan, Orion Enter Into Comtan Settlement Agreement; Takeda, Amylin Termination Agreement to Codevelop and Commercialize Compounds for Obesity; and More. Mylan Pharmaceuticals has entered into a ...

Pharmaceutical and biotechnology major Wockhardt has received US FDA approval for marketing a generic version of 200mg tablets containing Entacapone, which is used in the treatment of Parkinson’s ...

Mylan Inc. said Thursday that it had reached an agreement to settle patent litigation over the generic version of Orion Corp.'s Comtan. Mylan Inc. said Thursday that it had reached an agreement to ...

CHICAGO (Reuters) - Drugs used to treat Parkinson's disease show promise as a new way to stem the rise of drug-resistant forms of tuberculosis, U.S. researchers said on Thursday. They said computer ...

Sun Pharmaceutical Industries Ltd and its affiliates have settled a lawsuit filed by Orion in the United States against Sun Pharma over its abbreviated new drug applications (ANDAs) for generic ...